General Thoracic and Cardiovascular Surgery

, Volume 65, Issue 11, pp 622–626 | Cite as

Safety and effectiveness of tolvaptan for fluid management after pediatric cardiovascular surgery

  • Yuzo Katayama
  • Tsukasa Ozawa
  • Noritsugu Shiono
  • Hiroshi Masuhara
  • Takeshiro Fujii
  • Yoshinori Watanabe
Original Article
  • 413 Downloads

Abstract

Background

Postoperative fluid management is important after open heart surgery, because cardiopulmonary bypass evokes an abnormal inflammatory response and increases vascular permeability, especially in pediatric patients. We assessed the safety and effectiveness of tolvaptan for management of postoperative fluid retention after congenital heart surgery.

Methods and results

This retrospective study analyzed data from 43 children with uncomplicated congenital heart disease who underwent open heart surgery between September 2013 and August 2016. The patients were divided into two groups. Group N (n = 18; September 2013 through May 2014) received the conventional oral diuretics alone, and Group T (n = 25; June 2014 through August 2016) received a single dose of tolvaptan (0.45 mg/kg) in addition to the conventional oral diuretic therapy. Data were collected, while patients who received intensive care were assessed and compared between groups. Add-on tolvaptan use was associated with increased urinary output standardized by body weight (54.3 ± 4.5 vs 47.3 ± 19.1 mL/kg; p = 0.043), decreased additional intravenous diuretic dose standardized by body weight (0.26 ± 0.23 vs 0.62 ± 0.48 mg/kg; p = 0.001), and a smaller decrease in central venous pressure (1.3 ± 2.7 vs 1.9 ± 3.8 mmHg; p = 0.019). Laboratory analysis showed that electrolyte concentrations in blood and urine did not significantly differ between groups.

Conclusions

Tolvaptan appears to be effective and safe for management of postoperative fluid retention after congenital heart surgery.

Keywords

Diuretics Tolvaptan Surgery Congenital heart disease 

Notes

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest to disclose regarding this article.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Onogawa T, Sakamoto Y, Nakamura S, Nakayama S, Fujiki H, Yamamura Y. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure. Cardiovasc Drugs Ther. 2011;25(Suppl 1):S67–76.CrossRefPubMedGoogle Scholar
  2. 2.
    Murakami T, Horibata Y, Morimoto Y, Tateno S, Kawasoe Y, Niwa K. Syndrome of inappropriate secretion of antidiuretic hormone associated with angiotensin-converting enzyme inhibitor administration. Pediatr Cardiol. 2013;34:1261–3.CrossRefPubMedGoogle Scholar
  3. 3.
    Horibata Y, Murakami T, Niwa K. Effect of the oral vasopressin receptor antagonist tolvaptan on congestive cardiac failure in a child with restrictive cardiomyopathy. Cardiol Young. 2014;24:155–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Higashi K, Murakami T, Ishikawa Y, Itoi T, Ohuchi H, Kodama Y, et al. Efficacy and safety of tolvaptan for pediatric patients with congestive heart failure. Multicenter survey in the working group of the Japanese Society of PEdiatric Circulation and Hemodynamics (J-SPECH). Int J Cardiol. 2016;205:37–42.CrossRefPubMedGoogle Scholar
  5. 5.
    Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297:1332–43.CrossRefPubMedGoogle Scholar
  6. 6.
    Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet. 2008;371:1624–32.CrossRefPubMedGoogle Scholar
  7. 7.
    JCS Joint Working Group. Guidelines for treatment of acute heart failure (JCS 2011). Circ J. 2013;77:2157–201.CrossRefGoogle Scholar
  8. 8.
    Regen RB, Gonzalez A, Zawodniak K, Leonard D, Quigley R, Barnes AP, et al. Tolvaptan increases serum sodium in pediatric patients with heart failure. Pediatr Cardiol. 2013;34:1463–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Nishi H, Toda K, Miyagawa S, Yoshikawa Y, Fukushima S, Kawamura M, et al. Effects of tolvaptan in the early postoperative stage after heart valve surgery: results of the STAR (Study of Tolvaptan for fluid retention AfteR valve surgery) trial. Surg Today. 2015;45:1542–51.CrossRefPubMedGoogle Scholar
  10. 10.
    Kido T, Nishi H, Toda K, Ueno T, Kuratani T, Sakaki M, et al. Predictive factors for responders to tolvaptan in fluid management after cardiovascular surgery. Gen Thorac Cardiovasc Surg. 2016;. doi: 10.1007/s11748-016-0712-6.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Yamada M, Nishi H, Sekiya N, Horikawa K, Takahashi T, Sawa Y. The efficacy of tolvaptan in the perioperative management of chronic kidney disease patients undergoing open-heart surgery. Surg Today. 2016;. doi: 10.1007/s00595-016-1406-5.Google Scholar
  12. 12.
    Matsuyama K, Koizumi N, Nishibe T, Iwasaki T, Iwahasi T, Toguchi K, et al. Effects of short-term administration of tolvaptan after open heart surgery. Int J Cardiol. 2016;220:192–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Watanabe K, Dohi K, Sugimoto T, Yamada T, Sato Y, Ichikawa K, et al. Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure. J Cardiol. 2012;60:462–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Miura M, Sugimura K, Sakata Y, Miyata S, Tadaki S, Yamauchi T, et al. Prognostic impact of loop diuretics in patients with chronic heart failure—effects of addition of renin–angiotensin–aldosterone system inhibitors and beta-blockers. Circ J. 2016;80:1396–403.CrossRefPubMedGoogle Scholar
  15. 15.
    Tominaga N, Kida K, Matsumoto N, Akashi YJ, Miyake F, Kimura K, et al. Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/pharmacodynamics study. Clin Nephrol. 2015;84:29–38.CrossRefPubMedGoogle Scholar
  16. 16.
    Kato TS, Ono S, Kajimoto K, Kuwaki K, Yamamoto T, Amano A. Early introduction of tolvaptan after cardiac surgery: a renal sparing strategy in the light of the renal resistive index measured by ultrasound. J Cardiothorac Surg. 2015;10:143-015-0372-0.CrossRefGoogle Scholar
  17. 17.
    Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348–53.CrossRefPubMedGoogle Scholar
  18. 18.
    Kinugawa K, Sato N, Inomata T, Shimakawa T, Iwatake N, Mizuguchi K. Efficacy and safety of tolvaptan in heart failure patients with volume overload. Circ J. 2014;78:844–52.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Association for Thoracic Surgery 2017

Authors and Affiliations

  1. 1.Division of Cardiovascular Surgery, Department of SurgeryToho University Omori Medical CenterTokyoJapan

Personalised recommendations